Drug class
Phenothiazine antipsychotic; dopamine D2 and serotonin 5-HT2A receptor antagonist
Mechanism of action
Antagonises dopamine D2 receptors and serotonin 5-HT2A receptors, with additional antihistaminic, alpha-adrenergic and anticholinergic actions contributing to sedative and anxiolytic effects.
General use cases
- Treatment of schizophrenia and other psychotic disorders in countries where cyamemazine is authorised
- Some national product information includes short-term treatment of severe anxiety; do not generalise this to all cyamemazine formulations or jurisdictions
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
